CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Ranolazine

雷诺嗪 杂质对照品Ranolazine Impurities

USP34 个杂质条目34 impurity entries

本页汇总 雷诺嗪 的 34 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 34 impurity reference standards of Ranolazine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 雷诺嗪(Ranolazine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA novel reverse phase stability indicating RP-UPLC method for the quantitative determination of fifteen related substances in Ranolazine drug substance and drug product
    Talanta · 2012 · Malati V et al.  ·  PMID 22841123  ·  DOI
  2. 分析方法Analytical MethodsValidated RP-HPLC and Chromogenic UV Methods for Quantification of Ranolazine in Bulk, Plasma, and Nanoformulation as per ICH Q2(R2) and M10 Guidelines
    Chemistry & biodiversity · 2026 · Bhavya Sri K et al.  ·  PMID 42144825  ·  DOI
  3. 分析方法Analytical MethodsComparative AI-optimized HPLC-DAD strategy for the simultaneous determination of ranolazine, amlodipine, and diltiazem with pharmacotherapeutic relevance and multi-trait sustainability assessment
    Scientific reports · 2026 · Aboras SI et al.  ·  PMID 42034705  ·  DOI
  4. 分析方法Analytical MethodsDevelopment and validation of a sensitive LC-MS/MS assay for simultaneous quantitation of ranolazine and its three metabolites in human plasma
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2012 · Wang Y et al.  ·  PMID 22377406  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of ranolazine metabolites and their anti-myocardial ischemia activities
    Chemical & pharmaceutical bulletin · 2009 · Yao Z et al.  ·  PMID 19881270  ·  DOI

雷诺嗪 —— 原料药与杂质对照品Ranolazine — drug substance & impurities

共 35 个条目(含原料药本体)35 items incl. the drug substance
Ranolazine structure
USP原料药 APIAPI
雷诺嗪Ranolazine
Ranolazine
CAS No.95635-55-5
Chemical FormulaC24H33N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 27 (Ranolazine USP Related Compound A) structure
USPA
雷诺嗪杂质27 (雷诺嗪USP相关化合物A)Ranolazine Impurity 27 (Ranolazine USP Related Compound A)
Ranolazine Impurity 27 (Ranolazine USP Related Compound A)
CAS No.2210-74-4
Chemical FormulaC10H12O3
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 1 structure
1
雷诺嗪杂质1Ranolazine Impurity 1
Ranolazine Impurity 1
CAS No.380204-72-8
Chemical FormulaC24H32N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 2 structure
2
雷诺嗪杂质2Ranolazine Impurity 2
Ranolazine Impurity 2
CAS No.162712-35-8
Chemical FormulaC14H22N2O3
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 3 structure
3
雷诺嗪杂质3Ranolazine Impurity 3
Ranolazine Impurity 3
CAS No.333749-57-8
Chemical FormulaC24H34N2O6
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 4 structure
4
雷诺嗪杂质4Ranolazine Impurity 4
Ranolazine Impurity 4
CAS No.1427177-23-8
Chemical FormulaC17H26ClN3O2
Purity>95%现货In stock
10mg25mg50mg100mg
Ranolazine Impurity 4 structure
4
雷诺嗪杂质4Ranolazine Impurity 4
Ranolazine Impurity 4
CAS No.2731041-97-5
Chemical FormulaC24H33N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 5 structure
5
雷诺嗪杂质5Ranolazine Impurity 5
Ranolazine Impurity 5
CAS No.1246816-00-1
Chemical FormulaC24H33N3O6
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 6 structure
6
雷诺嗪杂质6Ranolazine Impurity 6
Ranolazine Impurity 6
CAS No.93-14-1
Chemical FormulaC10H14O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 7 structure
7
雷诺嗪杂质7Ranolazine Impurity 7
Ranolazine Impurity 7
CAS No.5294-61-1
Chemical FormulaC14H21N3O
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 8 structure
8
雷诺嗪杂质8Ranolazine Impurity 8
Ranolazine Impurity 8
CAS No.2725395-82-2
Chemical FormulaC24H33N3O5
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 9 structure
9
雷诺嗪杂质9Ranolazine Impurity 9
Ranolazine Impurity 9
CAS No.172430-48-7
Chemical FormulaC16H24N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 11 structure
11
雷诺嗪杂质11Ranolazine Impurity 11
Ranolazine Impurity 11
CAS No.1393717-45-7
Chemical FormulaC24H33N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 12 structure
12
雷诺嗪杂质12Ranolazine Impurity 12
Ranolazine Impurity 12
CAS No.1393717-46-8
Chemical FormulaC24H33N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 14 structure
14
雷诺嗪杂质14Ranolazine Impurity 14
Ranolazine Impurity 14
CAS No.1213269-66-9
Chemical FormulaC31H46N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 15 structure
15
雷诺嗪杂质15Ranolazine Impurity 15
Ranolazine Impurity 15
CAS No.13438-26-1
Chemical FormulaC8H12N2
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 17 structure
17
雷诺嗪杂质17Ranolazine Impurity 17
Ranolazine Impurity 17
CAS No.39262-25-4
Chemical FormulaC7H15ClN2O
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 18 structure
18
雷诺嗪杂质18Ranolazine Impurity 18
Ranolazine Impurity 18
CAS No.755711-09-2
Chemical FormulaC23H31N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 19 structure
19
雷诺嗪杂质19Ranolazine Impurity 19
Ranolazine Impurity 19
CAS No.29183-14-0
Chemical FormulaC10H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 20 structure
20
雷诺嗪杂质20Ranolazine Impurity 20
Ranolazine Impurity 20
CAS No.114246-80-9
Chemical FormulaC24H33N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 21 structure
21
雷诺嗪杂质21Ranolazine Impurity 21
Ranolazine Impurity 21
CAS No.114246-81-0
Chemical FormulaC24H33N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 22 structure
22
雷诺嗪杂质22Ranolazine Impurity 22
Ranolazine Impurity 22
CAS No.172430-45-4
Chemical FormulaC23H31N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 23 structure
23
雷诺嗪杂质23Ranolazine Impurity 23
Ranolazine Impurity 23
CAS No.172300-93-5
Chemical FormulaC29H39N3O10
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 24 structure
24
雷诺嗪杂质24Ranolazine Impurity 24
Ranolazine Impurity 24
CAS No.172430-46-5
Chemical FormulaC17H27N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 25 (N-Nitroso Ranolazine Impurity 7) structure
25
雷诺嗪杂质25 (N-亚硝基雷诺嗪杂质7)Ranolazine Impurity 25 (N-Nitroso Ranolazine Impurity 7)
Ranolazine Impurity 25 (N-Nitroso Ranolazine Impurity 7)
CAS No.3038740-93-8
Chemical FormulaC14H20N4O2
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 26 structure
26
雷诺嗪杂质26Ranolazine Impurity 26
Ranolazine Impurity 26
CAS No.122-42-9
Chemical FormulaC10H13NO2
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 29 (N-Nitroso Ranolazine Impurity 28) structure
29
雷诺嗪杂质29 (N-亚硝基雷诺嗪杂质28)Ranolazine Impurity 29 (N-Nitroso Ranolazine Impurity 28)
Ranolazine Impurity 29 (N-Nitroso Ranolazine Impurity 28)
CAS No.3104323-44-3
Chemical FormulaC14H21N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 30 structure
30
雷诺嗪杂质30Ranolazine Impurity 30
Ranolazine Impurity 30
CAS No.18102-31-3
Chemical FormulaC8H10O2
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 31 structure
31
雷诺嗪杂质31Ranolazine Impurity 31
Ranolazine Impurity 31
CAS No.93-51-6
Chemical FormulaC8H10O2
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 32 structure
32
雷诺嗪杂质32Ranolazine Impurity 32
Ranolazine Impurity 32
CAS No.100953-27-3
Chemical FormulaC12H10O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 33 structure
33
雷诺嗪杂质33Ranolazine Impurity 33
Ranolazine Impurity 33
CAS No.2724549-66-8
Chemical FormulaC34H45N3O7
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 35 structure
35
雷诺嗪杂质35Ranolazine Impurity 35
Ranolazine Impurity 35
CAS No.2851-82-3
Chemical FormulaC12H14O4
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 39 structure
39
雷诺嗪杂质39Ranolazine Impurity 39
Ranolazine Impurity 39
CAS No.141987-47-5
Chemical FormulaC10H13ClO3
Purity>95%询价On request
10mg25mg50mg100mg
Ranolazine Impurity 18-d5 structure
18-D5
雷诺嗪杂质18-d5Ranolazine Impurity 18-d5
Ranolazine Impurity 18-d5
CAS No.1794788-57-0
Chemical FormulaC23H26D5N3O3
Purity>95%询价On request
Ranolazine Impurity 22-d5 structure
22-D5
雷诺嗪杂质22-d5Ranolazine Impurity 22-d5
Ranolazine Impurity 22-d5
CAS No.1329834-18-5
Chemical FormulaC23H26D5N3O4
Purity>95%询价On request
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

雷诺嗪 —— 研究文献与合成路线Ranolazine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 雷诺嗪 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Ranolazine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A novel reverse phase stability indicating RP-UPLC method for the quantitative determination of fifteen related substances in Ranolazine drug substance and drug product
    Malati V, Reddy AR, Mukkanti K, et al. · Talanta · 2012 · 被引 7cited 7

合成与制备工艺专利Synthesis & process patents

  1. A PROCESS FOR THE PREPARATION OF RANOLAZINE
    SIYAN RAJINDER SINGH, GOHEL SUNILKUMAR VINUBHAI, WALUNJ RAJU, ANURAG SMART, et al. · 公开号 WO2010097805WO2010097805 · 2010
  2. PREPARATION OF RANOLAZINE
    ANUMULA RAGHUPATHI REDDY, GILLA GOVERDHAN, AALLA SAMPATH, MADIVADA LOKESWARA RAO, et al. · 公开号 US2011151258US2011151258 · 2011
  3. METHOD FOR PREPARATION OF RANOLAZINE
    SHI MINGFENG, LI DAN, XU LING · 公开号 WO2011160396WO2011160396 · 2011
  4. PREPARATION OF RANOLAZINE
    ANUMULA RAGHUPATHI REDDY, GILLA GOVERDHAN, AALLA SAMPATH, MADIVADA LOKESWARA RAO, et al. · 公开号 EP2328873EP2328873 · 2011
  5. PREPARATION OF RANOLAZINE
    ANUMULA RAGHUPATHI REDDY, GILLA GOVERDHAN, AALLA SAMPATH, MADIVADA LOKESWARA RAO, et al. · 公开号 WO2010025370WO2010025370 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

雷诺嗪 杂质谱研究要点Ranolazine — impurity profiling notes

下面这些是拿到 雷诺嗪 的 35 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 35 impurity entries for Ranolazine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances